StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Navidea Biopharmaceuticals stock opened at $0.00 on Monday. The firm has a market cap of $20,016.80, a price-to-earnings ratio of 0.00 and a beta of 0.76. The stock has a fifty day simple moving average of $0.03 and a two-hundred day simple moving average of $0.04. Navidea Biopharmaceuticals has a 12 month low of $0.00 and a 12 month high of $0.15.
About Navidea Biopharmaceuticals
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead
- Manufacturing Stocks Investing
- Progress Software Stock Back in the Green After Beating Forecasts
- The Role Economic Reports Play in a Successful Investment Strategy
- Goldman Sachs Raises Stock Target for Affirm: Key Insights
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.